These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 21453385

  • 1. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.
    Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
    Cancer Sci; 2011 Jul; 102(7):1388-95. PubMed ID: 21453385
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A, Razifar P, Ide S, Rugaard Jensen M, Josephsson R, Blomqvist C, Langström B, Bergström M.
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [Abstract] [Full Text] [Related]

  • 3. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ, Lazenby M, Pepper CJ, Knapper S, Burnett AK.
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [Abstract] [Full Text] [Related]

  • 4. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
    Kaiser M, Lamottke B, Mieth M, Jensen MR, Quadt C, Garcia-Echeverria C, Atadja P, Heider U, von Metzler I, Türkmen S, Sezer O.
    Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
    [Abstract] [Full Text] [Related]

  • 5. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.
    Okui T, Shimo T, Hassan NM, Fukazawa T, Kurio N, Takaoka M, Naomoto Y, Sasaki A.
    Anticancer Res; 2011 Apr; 31(4):1197-204. PubMed ID: 21508365
    [Abstract] [Full Text] [Related]

  • 6. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T, Australian Prostate Cancer BioResource, Tilley WD, Butler LM.
    Clin Cancer Res; 2012 Jul 01; 18(13):3562-70. PubMed ID: 22573351
    [Abstract] [Full Text] [Related]

  • 7. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C, Chène P.
    Breast Cancer Res; 2008 Jul 01; 10(2):R33. PubMed ID: 18430202
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
    Chen MH, Lin KJ, Yang WL, Kao YW, Chen TW, Chao SC, Chang PM, Liu CY, Tzeng CH, Chao Y, Chen MH, Yeh CN, Huang CY.
    Cancer; 2013 Jan 15; 119(2):293-303. PubMed ID: 22810956
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
    Canonici A, Qadir Z, Conlon NT, Collins DM, O'Brien NA, Walsh N, Eustace AJ, O'Donovan N, Crown J.
    Invest New Drugs; 2018 Aug 15; 36(4):581-589. PubMed ID: 29396630
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.
    Zaidi S, McLaughlin M, Bhide SA, Eccles SA, Workman P, Nutting CM, Huddart RA, Harrington KJ.
    PLoS One; 2012 Aug 15; 7(4):e35436. PubMed ID: 22523597
    [Abstract] [Full Text] [Related]

  • 16. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.
    Stühmer T, Zöllinger A, Siegmund D, Chatterjee M, Grella E, Knop S, Kortüm M, Unzicker C, Jensen MR, Quadt C, Chène P, Schoepfer J, García-Echeverría C, Einsele H, Wajant H, Bargou RC.
    Leukemia; 2008 Aug 15; 22(8):1604-12. PubMed ID: 18480838
    [Abstract] [Full Text] [Related]

  • 17. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
    Bao XH, Takaoka M, Hao HF, Fukazawa T, Yamatsuji T, Sakurama K, Takigawa N, Nakajima M, Fujiwara T, Naomoto Y.
    Oncol Rep; 2013 Jan 15; 29(1):45-50. PubMed ID: 23064324
    [Abstract] [Full Text] [Related]

  • 18. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.
    Cancer Sci; 2012 Feb 15; 103(2):342-9. PubMed ID: 22050138
    [Abstract] [Full Text] [Related]

  • 19. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
    Lee DH, Sung KS, Bartlett DL, Kwon YT, Lee YJ.
    Cell Signal; 2015 Feb 15; 27(2):293-305. PubMed ID: 25446253
    [Abstract] [Full Text] [Related]

  • 20. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.
    Taniguchi H, Hasegawa H, Sasaki D, Ando K, Sawayama Y, Imanishi D, Taguchi J, Imaizumi Y, Hata T, Tsukasaki K, Uno N, Morinaga Y, Yanagihara K, Miyazaki Y.
    Cancer Sci; 2014 Dec 15; 105(12):1601-8. PubMed ID: 25263741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.